RIWC2018_Auckland
“Retinal Degenerations – A Clinical Overview”
Elise Héon (Clinician-Scientist in the field of Ocular Genetics, Director of the Eye Genetics Program and Senior Associate Scientist at The Hospital for Sick Children Research Institute in the program of Genetics and Genomics Biology. Her laboratory : Professor, Department of Ophthalmology and Vision Science, University of Toronto)
“Progress in Therapy of Retinal Degeneration – The Who and the How”
Eric Pierce (M.D., Ph.D. is the Solman and Libe Friedman Professor of Ophthalmology, Director of the Ocular Genomics Institute, Director of the Berman-Gund Laboratory for the Study of Retinal Degenerations, and Director of the Inherited Retinal Disorders Service in the Department of Ophthalmology)
“Clinical diagnosis in Inherited Retinal Diseases – clues to the genetic diagnosis”
Andrea Vincent (Associate Professor , Ophthalmologist Clinician-Scientist, with overseas fellowship training in Ocular Genetics, to become the only Molecular Ophthalmologist in New Zealand, and Associate Professor in the Department of Ophthalmology, New Zealand National Eye centre, University of Auckland)
“Advances in Genetic Testing in Inherited Retinal Diseases”
Alex Hewitt (Principal Research Fellow at the Menzies Institute for Medical Research and the School of Medicine at the University of Tasmania, as well as a Principal Investigator at the Centre for Eye Research Australia)
”Novel/non-coding causes of Inherited Retinal Diseases”
Eric Pierce
”Identifying patients for clinical trials/The logistics of undertaking a clinical trial”
Jean Bennett (MD, PhD, the F.M. Kirby Professor of Ophthalmology, Professor of Cell and Developmental Biology, and Co-Director of the Center for Advanced Retinal and Ocular Therapeutics (CAROT) at the University of Pennsylvania Perelman School of Medicine)
“Progress and lessons learned from the UK Gene Therapy Trials”
Tom Edwards (Ph.D. vitreoretinal surgeon with an interest in inherited retinal degenerations. now based at the RVEEH and the Centre for Eye Research Australia (CERA) in Melbourne, Australia)
Parallel Session 1 Session 1A: Clinical aspects of Retinal Degenerations
1: “Prevalence and inheritance of Inherited Retinal Diseases – using databases as a tool” Andrea Vincent (Recording link)
2: “Developing patient relevant outcomes in clinical trials” Elise Héon (Recording link)
3:” Paediatric low vision and supportive services” Shuan Dai
(Recording link)
4:”Surgical considerations in Inherited Retinal Disease” Tom Edwards (Recording link)
5:”Treatment possibilities” Dan Chung (Spark Therapeutics)
(Recording link)
Q&A時間 (Recording link)
Plenary 3: Scientific Breaking News
1. Keynote: “Current and Emerging Gene Therapies for Inherited Retinal Disease” Professor Jean Bennett
Sponsored by The Ombler Trust
2.” ReNeuron Clinical Trial – Stem Cell base therapies” Eric Pierce
3. “New understandings of AMD Pathogenesis” Diane Sharp
( Dr Dianne Sharp, MBChB, FRACS, FRANZCO, graduated from Otago Medical School, completed Ophthalmology training in Auckland and a two-year medical retinal fellowship at Moorfields Eye Hospital in London. She works as a Medical Retina specialist, working with medical therapies for diseases of the retina including macular degeneration, diabetes and vascular diseases. These treatments include photodynamic therapy and intravitreal therapy with Avastin, Lucentis and Eylea. She established the Ophthalmic Electrodiagnostic units in Auckland which provide a diagnostic service for acquired and inherited retinal disorders. To assist the rehabilitation of patients she was involved in the establishment of a multidisciplinary visual rehabilitation clinic at Auckland Hospital and the patient support group, Retina NZ. ln 2009 she established Macular Degeneration New Zealand (MDNZ). This charitable trust aims to reduce the incidence and impact of MD in NZ.
Dianne has been a principal investigator in international trials involved in the treatment and management of diabetic macular oedema and macular degeneration. She is co-author of a number of scientific publications. She is a member of Retina International Scientific and Medical Advisory Board, Oceania Retina Association and ANZSRS (RANZCO special interest group). In 2017 she was awarded the RANZCO Distinguished Service Medal for services to ophthalmology including the establishment of Macular Degeneration NZ.)
4. “AMD therapeutic trials” Mark Gillies
(Professor Mark Gillies is a clinician-scientist who is Director of Research, Save Sight Institute, University of Sydney. The Macula Research Group’s (MRG) Clinical Research Unit has conducted several major investigator-initiated randomized clinical trials, including the first to demonstrate the efficacy of intraocular steroid injections for any ophthalmic disease. The MRG’s Observational Studies Unit has developed internet-based software to track the outcomes of treatment of macular disease. The main interests of the MRG’s laboratory include the relationships between retinal glia and neurons in retinal disease with particular interest in outer retinal metabolism. Mark was a founder member and for many years the Chair of the Scientific Executive Committee of the MacTel Project.)
5. “Robotic surgery in Inherited Retinal Disease” Tom Edwards
Plenary 4: Artificial Vision
1. Keynote: “Artificial Vision – Past, Present and Future” Tom Edwards
Sponsored by Fraser and Christina Alexander
2. “Bionic Vision Australia” Penny Allen
(Assoc Prof Allen received a Bachelor of Medicine and Surgery in 1986 from the University of Melbourne and specialised in Ophthalmology. She then sub-specialised in Vitreoretinal surgery and Medical Retina, completing fellowships at the Royal Victorian Eye and Ear Hospital and Moorfields Eye Hospital in London. Assoc Prof Allen was the lead surgeon for Bionic Vision Australia and Research Fellow at the Centre for Eye Research Australia, with clinical appointments at the Royal Victorian Eye and Ear Hospital and the Alfred Hospital. She holds an honorary research associate position with the Bionics Institute.
Assoc Prof Allen was a PI on the Australian Research Council (ARC) through its Special Research Initiative in Bionic Vision Science and Technology grant to Bionic Vision Australia (BVA) and has ongoing research support from the NHMRC, ORIA and the CASS foundation.
Assoc Prof Allen was key to the developing the surgical technique for the suprachoroidal retinal prosthesis, resulting in the first clinical trial of this device in three human patients. This collaboration has resulted in 2 licenced patents. Acknowledgement of this was her inclusion in the shortlist for an Australian Eureka prize for interdisciplinary research. Dr Allen’s research and publications on endophthalmitis have resulted in the development of protocols for the management of endophthalmitis at the Royal Victorian Eye and Ear Hospital and also resulted in a strategy to reduce the incidence of endogenous endophthalmitis in injecting drug users that was utilised across Victoria. In addition she was asked to advise regarding the endophthalmitis guidelines for the Epworth Hospital.)
3. “Argus 2 – the surgical procedure and clinical journey” Thiran Jayasundera
(Dr. Jayasundera is Associate Professor of Ophthalmology and Visual Sciences at the University of Michigan. His clinical practice is in vitreoretinal surgery, retinal dystrophies, electrophysiological testing, and posterior uveitis. His NIH funded research program focuses on inherited retinal degenerations – his goal is to identify patients at an earlier age to be able to 1) provide the correct genetic diagnosis, 2) give an accurate prognosis, 3) help guide the choice of treatment, such as gene therapy, and 4) develop outcome measures which will determine progression of their disease state in therapeutic trials.)
まとめ講演
What have we Learned and Where We are in Treating Retinal Degenerations ? : Companies, Glinical Trials and Cures
Gerald D. Chader （南カリフォルニア大学教授）
我々は網膜疾患研究について何を、どこまで学んだか？
（上記講演の日本語訳PDF版）
RIWC2016_Taipei
RIWC2014_Paris
